1466 — Baijin Life Science Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.54bn
- HK$1.54bn
- HK$89.30m
Annual cashflow statement for Baijin Life Science Holdings, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.5 | 8.73 | -8.53 | -1.36 | -43.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 11.1 | -30.3 | -14.8 | -1.46 | 3.66 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.15 | -1.4 | 15 | -34.4 | 22.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1.11 | -21.5 | -6.46 | -30.5 | -7.33 |
| Capital Expenditures | -0.046 | -0.026 | -0.179 | -2.44 | -15.4 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.014 | 35.3 | 4.92 | 1.6 | -0.492 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.06 | 35.3 | 4.74 | -0.846 | -15.9 |
| Financing Cash Flow Items | -3.55 | -0.067 | -0.037 | -0.966 | -4.51 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.72 | 3.7 | 0.819 | 41.4 | 18.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.839 | 17.7 | -3.38 | 9.89 | -4.66 |